What is LOPJLB’s current signal on SBFM?

LOPJLB’s latest quantitative signal on Sunshine Biopharma, Inc. (SBFM) is BUY in a CRISIS regime. Signals are updated daily.

What market regime is SBFM in?

Sunshine Biopharma, Inc. (SBFM) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Sunshine Biopharma, Inc. (SBFM) do?

Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, l…

Sunshine Biopharma, Inc. (SBFM)

COMPARE

Healthcare · Drug Manufacturers - Specialty & Generic · NASDAQ · US

$0.24-20.00%Close

BUYCRISIS · day 32

Company news

defenseworld.net · 2d ago

Sunshine Biopharma, Inc. (NASDAQ:SBFM) Sees Significant Growth in Short Interest

accessnewswire.com · 5d ago

Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering

accessnewswire.com · 7d ago

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

zacks.com · 20d ago

Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know

accessnewswire.com · 20d ago

Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio

accessnewswire.com · 28d ago

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

accessnewswire.com · 44d ago

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

accessnewswire.com · 49d ago

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

accessnewswire.com · 56d ago

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

accessnewswire.com · 68d ago

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

accessnewswire.com · 71d ago

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

benzinga.com · 71d ago

EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval

defenseworld.net · 77d ago

Reviewing Foghorn Therapeutics (NASDAQ:FHTX) and Sunshine Biopharma (NASDAQ:SBFM)

accessnewswire.com · 79d ago

Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

accessnewswire.com · 86d ago

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

defenseworld.net · 88d ago

Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 35.0% in June

Market news & ticker search · RSS for SBFM

FAQ

What is LOPJLB’s current signal on SBFM?: LOPJLB’s latest quantitative signal on Sunshine Biopharma, Inc. (SBFM) is BUY in a CRISIS regime. Signals are updated daily.
What market regime is SBFM in?: Sunshine Biopharma, Inc. (SBFM) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Sunshine Biopharma, Inc. (SBFM) do?: Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, l…

Sunshine Biopharma, Inc. (SBFM)

Key stats

Prediction markets

Company news

FAQ